Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Not all retirees benefit equally from Target Date Funds. This guide points out scenarios and preferences where avoidance may be wise.
27,346 articlesThe gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Hydrogen stocks have captured attention in 2026. This guide pits Plug Power against FuelCell Energy, cutting through ...
In 2026, investors face a pivotal choice between the world's largest gold producer and a nimble challenger. This arti...
Oregon's push to shift recycling costs to manufacturers promised cleaner streets and better recycling, but the rollou...
Trauma can leave a lasting imprint on how we handle money. This article explores how the feeling it feels like weight...
A newly released inspector general report into a Bridgeport shooting finds the pursuit justified but highlights ambul...
Fluence Energy’s stock surged after-hours on news of two hyperscaler storage deals, even as Q2 revenue disappointed. ...
A broad rally in semiconductor stocks persists into late May 2026, driven by AI infrastructure demand. Yet history ca...
Oil prices surge and inflation concerns persist, lifting the market meltdown odds to 35% as investors reassess growth...
Forbes' 2026 Billionaires List puts Binance founder CZ ahead of Bill Gates, prompting debate over crypto wealth and h...
SanDisk has enjoyed a dramatic rally, but traders are wrestling with whether the rally can run further as memory cycl...
Virgin Galactic’s stock having its worst day after a debt-paydown plan triggered dilution fears, snapping a seven-day...